or
forgot password
  • cancer clinical trials in farmington, CT

  • Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Neuroblastoma
    Combination Chemotherapy in Treating Children or Adolescents With Newly Diagnosed Stage III or Stage IV Lymphoblastic Lymphoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lymphoma
    Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
    Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Chronic Hepatitis C, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
    Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lymphoma
    Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Head and Neck Cancer, Oral Complications, Radiation Toxicity
    Lobradimil and Carboplatin in Treating Children With Brain Tumors
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Brain and Central Nervous System Tumors
    Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lymphoma
    Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Neoplasms
    Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia,Myeloid, Chronic, Leukemia,Myeloid,Philadelphia-Positive
    Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain Tumor, Central Nervous System Tumor
    Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
    Univ. of Connecticut Health Center
    Farmington, Connecticut 06030
    Carcinoma, Metastatic Breast
    Chemoprevention of Oral Premalignant Lesions
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Precancerous Conditions
    Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Leukemia, Myelocytic, Acute, Pediatric
    PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Melanoma, Breast Neoplasms, Carcinoma, Renal Cell, Lymphoma, T-Cell, Carcinoma, Non-Small-Cell Lung
    CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Breast
    Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
    Clinical Trial for Ovarian Cancer (OvaRex®)
    University of Connecticut Cancer Center
    Farmington, Connecticut 06030
    Ovarian Cancer
    Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Pancreatic Cancer
    Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lymphoma
    Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Renal Cell, Kidney Neoplasms
    Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia
    Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Lymphoma
    Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Renal Cell
    Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain Tumor, Central Nervous System Tumor
    Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
    Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Colorectal Neoplasms
    TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
    University of Connecticut Health Center/John Dempsey Hospital
    Farmington, Connecticut 06030
    Ovarian Neoplasms
    Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Brain and Central Nervous System Tumors
    Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Lymphoma
    Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Renal Cell
    Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Colorectal Neoplasms
    Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Osteoporosis
    AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Pancreatic Neoplasms
    Safety and Tolerability of Repeat Courses of IM Alefacept
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Chronic Plaque Psoriasis
    Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Renal Cell
    Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Neuroblastoma
    Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Non-Small-Cell Lung
    High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Non-Small Cell Lung Cancer
    A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Breast Neoplasms
    Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer, Stage 4 Cancer
    Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Ovarian Cancer
    Expanded Access Program for Maraviroc At Multiple Centers
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Advanced HIV Infection
    Registration and Informed Consent Study for the Childhood Cancer Research Network
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Unspecified Childhood Solid Tumor, Protocol Specific
    A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Non-Small Cell Lung
    Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Renal Cell Carcinoma
    Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
    Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
    BioSante Site 166
    Farmington, Connecticut 06032
    Hypoactive Sexual Desire Disorder
    Follow-Up Study for Exubera
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Diabetes Mellitus
    Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
    Farmington, Connecticut 06360-2875
    Sarcoma
    Anastrozole and Letrozole
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Breast Cancer
    Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Cancer-related Fatigue
    Dental Study in Cancer Patients With Central Venous Catheters
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Cancer
    Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Menopause, Osteoporosis
    Long-term Follow-up of HALT-C Sustained Virological Responders
    Univ. of Connecticut Health Center
    Farmington, Connecticut 06030
    Hepatitis C, Hepatocellular Carcinoma, Ascites, Variceal Hemorrhage, Death
    Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Prostate Cancer
    Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Bladder Neoplasm, Intravesical Drug Administration, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
    Colonoscope Insertion Trial Protocol
    University of Connecticut Health Center
    Farmington, Connecticut 06360-7106
    Colorectal Cancer
    Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
    Pfizer Investigational Site
    Farmington, Connecticut 06030-3805
    Gram Positive Infection